Report on Provenge for CMS Confirms Vaccine's Effectiveness

摘要

As the Centers for Medicare & Medicaid Services (CMS) prepares to consider the evidence for extending coverage to Dendreon's prostate cancer drug Provenge, an independent review has failed to raise red flags about its effectiveness.